Last $72.45 USD
Change Today +2.17 / 3.09%
Volume 5.9M
As of 6:40 PM 12/18/14 All times are local (Market data is delayed by at least 15 minutes).

eli lilly & co (LLY) Key Developments

Eli Lilly and Company Announces Increased Quarterly Dividend Payable on March 10, 2015

The board of directors of Eli Lilly and Company announced a 2% increase in its quarterly dividend. The board has declared a dividend for the first quarter of 2015 of $0.50 per share on outstanding common stock. This raises the annual indicated rate to $2.00 per share. The dividend is payable on March 10, 2015 to shareholders of record at the close of business on February 13, 2015. The increase in its dividend signals continued confidence in Lilly's future and confirms its commitment to return additional cash to shareholders.

Eli Lilly's Cyramza Receives Expanded US FDA Approval for NSCLC

The US FDA has announced that it has expanded approval of Eli Lilly's Cyramza (ramucirumab) in combination with docetaxel for the treatment of metastatic non-small-cell lung cancer (NSCLC) in patients who have experienced disease progression during or following platinum-based chemotherapy. The regulatory approval of the supplemental Biologics Licence Application was based on data from a clinical trial that enrolled 1,253 patients and demonstrated that patients taking Cyramza with docetaxel survived on average longer (10.5 months) compared with those on docetaxel alone (9.1 months). Most commonly reported side-effects include neutropenia, fatigue, and stomatitis.

Eli Lilly and Company, Anthem, Inc. and HealthCore Inc. Create Research Collaboration to Improve Health Outcomes

Eli Lilly and Company, Anthem, Inc. and HealthCore, Inc. announced that they have formed a five-year, real-world evidence research collaboration intended to improve health outcomes for patients. The companies will jointly develop and conduct research projects in health outcomes and real-world evidence in areas of mutual interest. Each party will bring distinct and valuable contributions to the collaboration, including the U.S. provider and patient environment, research capabilities, therapeutics and methods expertise, and integrated, researchable data. The collaboration allows the organizations to explore research opportunities across disease states and incorporate surveys and other information from providers and patients.

AstraZeneca PLC and Eli Lilly and Company Enroll First Patient in Phase II/III Alzheimer's Study

AstraZeneca plc and Eli Lilly and Company have enrolled the first patient into AMARANTH, a Phase II/III study of an oral beta secretase cleaving enzyme, or BACE, inhibitor currently in development as a treatment for Alzheimer's disease. AZD3293, also known as LY3314814, has been shown in Phase I studies to reduce levels of amyloid-beta in the cerebro-spinal fluid of Alzheimer's patients and healthy volunteers. The progression of Alzheimer's disease is characterized by the accumulation of amyloid plaque in the brain. BACE is an enzyme associated with the development of beta-amyloid. Inhibiting BACE is expected to prevent the formation of amyloid plaque and eventually slow the progression of the disease. The pivotal study will investigate the safety and efficacy of AZD3293/LY3314814 compared with placebo in the treatment of early Alzheimer's disease.

Eli Lilly and Company and AstraZeneca Initiate Pivotal Clinical Trial for Patients with Early Alzheimer's Disease

Eli Lilly and Company and AstraZeneca announced enrollment of the first patient into AMARANTH, a Phase II/III study of an oral beta secretase cleaving enzyme (BACE) inhibitor currently in development as a potential treatment for Alzheimer's disease. AZD3293, also known as LY3314814, has been shown in Phase I studies to reduce levels of amyloid-beta in the cerebro-spinal fluid of Alzheimer's patients and healthy volunteers. The progression of Alzheimer's disease is characterized by the accumulation of amyloid plaque in the brain. BACE is an enzyme associated with the development of beta-amyloid. Inhibiting BACE is expected to prevent the formation of amyloid plaque and eventually slow the progression of the disease. The pivotal study will investigate the safety and efficacy of AZD3293/LY3314814 compared with placebo in the treatment of early Alzheimer's disease. AstraZeneca and Lilly announced an alliance earlier in 2014 for the development and commercialization of AZD3293/LY3314814. Under the agreement, Lilly will lead clinical development, working with researchers from AstraZeneca's Neuroscience Innovative Medicines Unit, while AstraZeneca will be responsible for manufacturing. The companies will take joint responsibility for commercialization of the molecule and will share all future costs equally for development and commercialization, as well as net global revenues post-launch.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
LLY:US $72.45 USD +2.17

LLY Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Abbott Laboratories $45.77 USD +1.51
AbbVie Inc $67.92 USD +1.35
AstraZeneca PLC 4,573 GBp +123.50
Novo Nordisk A/S kr266.50 DKK +6.60
Teva Pharmaceutical Industries Ltd $56.65 USD +0.90
View Industry Companies
 

Industry Analysis

LLY

Industry Average

Valuation LLY Industry Range
Price/Earnings 27.9x
Price/Sales 3.7x
Price/Book 4.2x
Price/Cash Flow 28.8x
TEV/Sales 3.3x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ELI LILLY & CO, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.